<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080728</url>
  </required_header>
  <id_info>
    <org_study_id>Jazayeri-Steinmetz AOI 2012</org_study_id>
    <nct_id>NCT02080728</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane Block During Kidney Transplant Surgery</brief_title>
  <official_title>Transversus Abdominis Plane Block During Kidney Transplant Surgery: Prospective Controlled Randomized Double-blind Trial Comparing Ropivacaine 0.2% With Placebo.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      The surgeon places the catheter in the thickness of the oblique internal and transverse
      muscles at the moment the wall is closed, under visual control. A multiperforated catheter
      whose length corresponds to that of the incision is chosed. The catheter will deliver one of
      two products chosen at random: either ropivacaine or placebo.

      This study will evaluate postoperative pain during the first 24 hours thanks to a recognized
      indicator the VAS (Visual Analogue pain Scale). The total consumption of analgesics will also
      be recorded, starting with the titration of morphine in the post-op room, and then the
      consumption of classical analgesics in the nephrology department. These will only be given if
      the VAS score is equal to 4 or above.

      This is a prospective, single-centre, controlled, double blind study of ropivacaïne 0.2%
      versus placebo in continuous TAP block during the first 24 hours after the operation in
      patients undergoing kidney transplant surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2013</start_date>
  <completion_date type="Actual">July 9, 2014</completion_date>
  <primary_completion_date type="Actual">July 9, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mesurement of VAS (Visual analogue scale) scores for pain</measure>
    <time_frame>During the first 24 hours post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of analgesic consomption</measure>
    <time_frame>During the first 24 hours post-op</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>TAP-Bloc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 500mg/100ml Naropeine</intervention_name>
    <arm_group_label>TAP-Bloc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride BAXTER</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient opéré for kidney transplant

          -  Patients who have provided written informed consent

          -  Patients with national health insurance cover

          -  Patients aged 18 years and above

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  allergies/hypersensitivity to paracetamol (or propacetamol chlorhydrate (paracetamol
             pro-drug) or one of its excipients), to local anesthetics, morphines (or other
             constituents)

          -  patients under guardianship or ward of court
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 5, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

